TRIUMPH-1 confirmed 28.3% at 80 weeks in 2,339 patients (May 21, 2026) results consistent with bariatric surgery outcomes
In large-scale studies, semaglutide (the active ingredient in Ozempic and Wegovy) led to an average placebo-corrected weight loss of about 12.4% at the 2.4 mg dose
GLP-1 RAs directly activate the GLP-1 receptor, which stimulates pancreatic insulin secretion in a glucose-dependent manner while also inhibiting glucagon secretion [8]
You can read the full article at The Effect of Tesofensine on Weight Loss, Appetite, Physical Activity and QOL in Obese Subjects
This is why the Phase 3 topic should sit inside the blog, not replace the safety message
Ozempic and Wegovy contain semaglutide, but they have different labeled uses